Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 93.96% is in line with its 5-year average of 89.56%, around the middle of its 5-year range (81.84%–100.00%).
1.48% above its 12-month average of 92.59%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 95.24%.
GROSS MARGIN
93.96%
GROSS MARGIN AVG TTM
92.59%
GROSS MARGIN AVG 3Y
87.67%
GROSS MARGIN AVG 5Y
89.56%
GROSS MARGIN AVG 10Y
91.07%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+1.48%
CURRENT VS 3Y AVG
+7.18%
CURRENT VS 5Y AVG
+4.92%
CURRENT VS 10Y AVG
+3.17%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+128.03%
vs the sector median at left
Market Cap
$816.13M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$828.48M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$833.81M
Gross Margin
92.94%
TTM Avg
91.25%
3Y Avg
45.63%
5Y Avg
30.42%
Market Cap
$838.16M
Gross Margin
58.31%
TTM Avg
55.25%
3Y Avg
65.77%
5Y Avg
65.77%
Market Cap
$838.62M
Gross Margin
35.97%
TTM Avg
27.94%
3Y Avg
30.11%
5Y Avg
34.47%
Market Cap
$789.34M
Gross Margin
94.30%
TTM Avg
95.84%
3Y Avg
95.72%
5Y Avg
72.44%
Market Cap
$785.03M
Gross Margin
10.37%
TTM Avg
19.20%
3Y Avg
18.44%
5Y Avg
17.81%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ardelyx, Inc. (ARDX) | $817.67M | 93.96% | 92.59% | 87.67% | 89.56% |
| Jade Biosciences, Inc. (JBIO)vs › | $816.13M | 0.00% | 0.00% | 0.00% | 0.00% |
| SpyGlass Pharma, Inc. Common Stock (SGP)vs › | $828.48M | 0.00% | 0.00% | 0.00% | 0.00% |
| InMode Ltd. (INMD)vs › | $804.16M | 76.52% | 79.43% | 81.57% | 82.72% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $833.81M | 92.94% | 91.25% | 45.63% | 30.42% |
| Beta Bionics, Inc. (BBNX)vs › | $838.16M | 58.31% | 55.25% | 65.77% | 65.77% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $838.62M | 35.97% | 27.94% | 30.11% | 34.47% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $789.34M | 94.30% | 95.84% | 95.72% | 72.44% |
| AdaptHealth Corp. (AHCO)vs › | $785.03M | 10.37% | 19.20% | 18.44% | 17.81% |
| SL Science Holding Ltd (SLBT)vs › | $852.35M | 35.27% | 46.37% | 58.90% | 58.90% |
Gross Margin
94.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 95.24% |
| 2026-03-31 | 94.91% |
| 2025-12-31 | 90.60% |
| 2025-09-30 | 95.57% |
| 2025-06-30 | 86.65% |
| 2025-03-31 | 82.59% |
| 2024-12-31 | 84.27% |
| 2024-09-30 | 83.99% |
| 2024-06-30 | 86.34% |
| 2024-03-31 | 83.57% |
| 2023-12-31 | 85.23% |
| 2023-09-30 | 86.36% |
| 2023-06-30 | 84.38% |
| 2023-03-31 | 86.48% |
| 2022-12-31 | 92.84% |
| 2022-09-30 | 85.32% |
| 2022-06-30 | 94.54% |
| 2022-03-31 | 81.84% |
| 2021-12-31 | 100.00% |
| 2021-09-30 | 100.00% |
| 2021-06-30 | 100.00% |
| 2021-03-31 | 84.81% |
| 2020-12-31 | 99.78% |
| 2020-09-30 | 100.00% |
| 2020-06-30 | 92.32% |
| 2020-03-31 | 100.00% |
| 2019-12-31 | 100.00% |
| 2019-09-30 | 80.09% |
| 2019-06-30 | 100.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 100.00% |
| 2018-09-30 | 98.84% |
| 2018-06-30 | 100.00% |
| 2018-03-31 | 80.00% |
| 2017-12-31 | 80.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 100.00% |
| 2015-03-31 | 100.00% |
| 2014-12-31 | 100.00% |
| 2014-09-30 | 100.00% |
| 2014-06-30 | 100.00% |
| 2014-03-31 | 100.00% |
| 2013-12-31 | 100.00% |
| 2013-09-30 | 100.00% |
| 2013-06-30 | 100.00% |
| 2013-03-31 | 100.00% |
